keyword
https://read.qxmd.com/read/38647656/dual-pathway-inhibition-in-patients-with-chronic-limb-threatening-ischemia-requiring-reintervention-for-infrapopliteal-occlusions
#1
JOURNAL ARTICLE
Burak Teymen, Mehmet Emin Öner, Yiğit Erdağ
Our study aimed to assess the influence of incorporating new oral anticoagulant (NOAC) therapy on clinical outcomes among patients who underwent endovascular intervention for below-the-knee (BTK) occlusions necessitating reintervention. The inclusion criteria encompassed patients with chronic limb-threatening ischemia (CLTI) and had undergone a successful endovascular intervention for BTK artery occlusion, necessitating reintervention. Patients who underwent endovascular interventions for BTK reocclusion were compared to those who received dual-pathway inhibition with NOAC (rivaroxaban 2...
April 22, 2024: Heart and Vessels
https://read.qxmd.com/read/38642461/preoperative-aspirin-and-anticoagulants-do-not-affect-partial-nephrectomy-bleeding
#2
JOURNAL ARTICLE
Muqsit Buchh, Courtney Yong, Fezaan Kazi, Ali Sualeh, James Slaven, Ronald S Boris, Chandru P Sundaram
INTRODUCTION: Studies have reached mixed conclusions on the role of antiplatelet and anticoagulant agents on postoperative complications of partial nephrectomies. This study examines whether preoperative anticoagulation use affected the risk of hemorrhagic complications after partial nephrectomy. MATERIALS AND METHODS: This is a retrospective chart review of all partial nephrectomies performed between 2017 and 2022 at a single institution. For each operation, preoperative data was gathered on whether the patient was on anticoagulation, the type and dose of anticoagulation, and how many days the anticoagulation was held preoperatively...
April 2024: Canadian Journal of Urology
https://read.qxmd.com/read/38634693/the-impact-of-preprocedural-platelet-function-testing-on-periprocedural-complication-rates-associated-with-pipeline-flow-diversion-an-international-multicenter-study
#3
JOURNAL ARTICLE
Justin E Vranic, Adam A Dmytriw, Inka K Berglar, Naif M Alotaibi, Nicole M Cancelliere, Christopher J Stapleton, James D Rabinov, Pablo Harker, Rajiv Gupta, Joshua D Bernstock, Matthew J Koch, Scott B Raymond, Justin R Mascitelli, T Tyler Patterson, Joshua Seinfeld, Andrew White, David Case, Christopher Roark, Chirag D Gandhi, Fawaz Al-Mufti, Jared Cooper, Charles Matouk, Nanthiya Sujijantarat, Diego A Devia, Maria I Ocampo-Navia, Daniel E Villamizar-Torres, Juan C Puentes, Mohamed M Salem, Ammad Baig, Kareem El Namaani, Anna Luisa Kühn, Bryan Pukenas, Brian T Jankowitz, Jan Karl Burkhardt, Adnan Siddiqui, Pascal Jabbour, Jasmeet Singh, Ajit S Puri, Robert W Regenhardt, Vitor Mendes Pereira, Aman B Patel
BACKGROUND AND OBJECTIVES: Dual antiplatelet therapy (DAPT) is necessary to minimize the risk of periprocedural thromboembolic complications associated with aneurysm embolization using pipeline embolization device (PED). We aimed to assess the impact of platelet function testing (PFT) on reducing periprocedural thromboembolic complications associated with PED flow diversion in patients receiving aspirin and clopidogrel. METHODS: Patients with unruptured intracranial aneurysms requiring PED flow diversion were identified from 13 centers for retrospective evaluation...
April 18, 2024: Neurosurgery
https://read.qxmd.com/read/38633322/decreased-incidence-of-kawasaki-disease-in-south-korea-during-the-sars-cov-2-pandemic
#4
JOURNAL ARTICLE
Kyung Jin Oh, Sang-Yun Lee
PURPOSE: Analyzing Kawasaki disease epidemiology during the SARS-CoV-2 pandemic in South Korea using 2012-2020 National Health Insurance Service data. METHODS: The incidence of Kawasaki disease for 2012-2020 was investigated to identify changes in incidence after the start of the pandemic. National Health Insurance Service data from the Republic of Korea were used. Kawasaki disease was defined based on the International Statistical Classification of Diseases and Related Health Problems, the Tenth Revision diagnostic code (M30...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38630489/extended-clopidogrel-monotherapy-vs-dapt-in-patients-with-acute-coronary-syndromes-at-high-ischemic-and-bleeding-risk-the-opt-birisk-randomized-clinical-trial
#5
JOURNAL ARTICLE
Yi Li, Jing Li, Bin Wang, Quanmin Jing, Yujie Zeng, Aijie Hou, Zhifang Wang, Aijun Liu, Jinliang Zhang, Yaojun Zhang, Ping Zhang, Daming Jiang, Bin Liu, Jiamao Fan, Jun Zhang, Li Li, Guohai Su, Ming Yang, Weihong Jiang, Peng Qu, Hesong Zeng, Lu Li, Miaohan Qiu, Leisheng Ru, Shaoliang Chen, Yujie Zhou, Shubin Qiao, Gregg W Stone, Dominick J Angiolillo, Yaling Han
IMPORTANCE: Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk). OBJECTIVE: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS)...
April 17, 2024: JAMA Cardiology
https://read.qxmd.com/read/38626078/antiplatelet-de-escalation-strategies-in-patients-undergoing-percutaneous-coronary-intervention
#6
REVIEW
Alessandro Spirito, Sriya L Krishnan, Davide Capodanno, Dominick J Angiolillo, Roxana Mehran
Dual antiplatelet therapy-the combination of aspirin and a P2Y12 inhibitor-remains the standard antiplatelet regimen recommended to prevent ischemic complications immediately after percutaneous coronary intervention. Nonetheless, recent advances in stent technologies, percutaneous coronary intervention techniques, adjunctive pharmacotherapy for secondary prevention, and the rising awareness of the prognostic impact of bleeding, which are inevitably associated with dual antiplatelet therapy, led to the investigation of alternative antiplatelet regimens related to fewer bleeding and a preserved ischemic protection...
April 2024: Circulation. Cardiovascular Interventions
https://read.qxmd.com/read/38604534/ventriculoperitoneal-shunt-placement-safety-in-idiopathic-normal-pressure-hydrocephalus-anticoagulated-versus-non-anticoagulated-patients
#7
JOURNAL ARTICLE
Abdelrahman M Hamouda, Zach Pennington, Mahnoor Shafi, Maria D Astudillo Potis, Hannah Hallak, Jonathan Graff-Radford, David T Jones, Hugo Botha, Jeremy K Cutsforth-Gregory, Petrice M Cogswell, Benjamin D Elder
BACKGROUND: Many patients with idiopathic normal pressure hydrocephalus (iNPH) have medical comorbidities requiring anticoagulation that could negatively impact outcomes. This study evaluated the safety of ventriculoperitoneal shunt (VPS) placement in iNPH patients on systemic anticoagulation versus those not on anticoagulation. METHODS: Patients > 60 years of age with iNPH who underwent shunting between 2018 and 2022 were retrospectively reviewed. Baseline demographics, comorbidities (quantified by modified Frailty Index (mFI) and Charlson Comorbidity Index (CCI)), anticoagulant/antiplatelet agent use (other than aspirin), operative details, and complications were collected...
April 9, 2024: World Neurosurgery
https://read.qxmd.com/read/38601241/bleeding-after-dental-extraction-in-patients-undergoing-percutaneous-coronary-intervention-during-uninterrupted-single-and-dual-antiplatelet-therapy
#8
JOURNAL ARTICLE
Amir Yari, Hassan Rajabi Moghadam, Mahdi Erfanian Taghvaei, Mina Asadi Keshe, Paniz Fasih
PURPOSE: This study aimed to assess bleeding risk after exodontia in patients with recent percutaneous coronary intervention during uninterrupted single or dual antiplatelet therapy. STUDY DESIGN: A total of 100 patients who had a history of percutaneous stent insertion during the past year candidate for extraction of teeth were included in the study. Fifty patients took aspirin 100mg (monotherapy group), and 50 patients took a combination of aspirin 100mg and clopidogrel 75mg (dual therapy group)...
April 2024: Journal of Maxillofacial and Oral Surgery
https://read.qxmd.com/read/38590611/the-prevalence-of-cardiovascular-diseases-chronic-kidney-disease-and-obesity-in-patients-with-type-2-diabetes-mellitus-and-the-description-of-concurrent-treatments-a-two-center-retrospective-cross-sectional-study-in-saudi-arabia
#9
JOURNAL ARTICLE
Omar A Alshaya, Ghazwa B Korayem, Munirah Alghwainm, Wed Alyami, Albandari Alotaibi, Majed S Alyami, Omar A Almohammed
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), and obesity are associated with increased morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Nonetheless, their prevalence among patients with T2DM in Saudi Arabia (SA) remains unknown. As current guidelines recommend, these comorbidities require adding certain antidiabetic agents with cardiorenal benefits. However, the prescribers' adherence to these recommendations remains unclear...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38586173/sex-based-outcomes-on-unguided-de-escalation-from-ticagrelor-to-clopidogrel-in-stabilized-patients-with-acute-myocardial-infarction-undergoing-percutaneous-coronary-intervention-a-post-hoc-analysis-of-the-talos-ami
#10
JOURNAL ARTICLE
Eun-Seok Shin, Eun Jung Jun, Bitna Kim, Chan Joon Kim, Mahn-Won Park, Eun-Ho Choo, Byung-Hee Hwang, Kwan Yong Lee, Gyu-Chul Oh, Min Chul Kim, Hyeon Woo Yim, Youngkeun Ahn, Kiyuk Chang
BACKGROUND: The TALOS-AMI study highlighted the effectiveness of a de-escalation strategy shifting from ticagrelor to clopidogrel 1 month after percutaneous coronary intervention (PCI), resulting in significant reduction in clinical events, primarily attributed to a substantial decrease in bleeding events. Nevertheless, the impact of this strategy on outcomes based on sex remains unclear. METHODS: This was a post-hoc analysis of the TALOS-AMI study. At 1 month after PCI, patients who remained adherent to aspirin and ticagrelor without experiencing major adverse events were randomized into either the de-escalation group (clopidogrel plus aspirin) or the active control group (ticagrelor plus aspirin) for an additional 12 months...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38582734/clopidogrel-induced-reduction-in-neutrophil-count-an-overlooked-beneficial-effect
#11
JOURNAL ARTICLE
Stefano De Servi, Antonio Landi, Stefano Savonitto
Complement-stimulated neutrophils are able to adhere to the endothelium and damage endothelial cells both in vitro and in vivo. These blood cells participate in the early stages, growth and complications of atherosclerotic plaques. Recent findings, based on mendelian randomization analysis, support the concept that high neutrophil counts are a causal risk factor for ischemic heart disease and myocardial infarction . Clopidogrel decreases leukocyte count and inflammatory markers in patients with acute coronary syndromes; this off-target effect, which is independent of the antiplatelet action, may help explaining secondary prevention data showing a superiority of clopidogrel over aspirin in reducing new cardiovascular events...
April 5, 2024: European Journal of Internal Medicine
https://read.qxmd.com/read/38580815/ticagrelor-versus-clopidogrel-in-dual-antiplatelet-therapy-after-minor-stroke-or-transient-ischemic-attack-an-updated-network-meta-analysis
#12
REVIEW
Gabriel Marinheiro, Beatriz Araújo, Gabriel de Almeida Monteiro, Marianna Leite, Antonio Mutarelli, Artur Menegaz de Almeida, Joaquim Francisco Cavalcante-Neto, André Rivera, Agostinho C Pinheiro, João Paulo Mota Telles
BACKGROUND: Dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin is a well-established practice after a minor stroke or transient ischemic attack (TIA). However, ticagrelor plus aspirin may be an alternative. AIMS: We systematically searched PubMed, Embase, and Cochrane Central from inception to January 2024. We included randomized controlled trials (RCTs) enrolling adults with acute minor stroke or TIA within 72 hours of the onset of the symptoms...
April 5, 2024: Journal of Neurology
https://read.qxmd.com/read/38580158/individualized-antiplatelet-therapy-for-non-cardiogenic-ischemic-stroke
#13
JOURNAL ARTICLE
Yifan Zhang, Moli Wang, Shengyuan Su
OBJECTIVE: This research aims to investigate the impact of individualized antiplatelet therapy guided by thromboelastography with platelet mapping (TEG-PM) on the clinical outcomes of patients with non-cardiogenic ischemic stroke. METHODS: Among a total of 1264 patients, 684 individuals diagnosed with non-cardiogenic ischemic stroke underwent TEG-PM testing. Based on the adjustment of antiplatelet medication, these patients were divided into individual and control groups...
April 3, 2024: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://read.qxmd.com/read/38575061/flow-diverter-combined-with-coil-embolization-for-acutely-ruptured-intracranial-aneurysms-a-single-center-experience
#14
JOURNAL ARTICLE
Jie Liu, Liyun Zhou, Yuhui Ling, Xiuzhi Xiang, Peiming Wang
BACKGROUND AND PURPOSE: Extensive research has confirmed the safety and effectiveness of flow diverters in the treatment of unruptured intracranial aneurysms. However, their use in cases of acute rupture remains a subject of debate. METHODS: This study was conducted as a single-center retrospective investigation from January 2018 to January 2022 and included patients with acutely ruptured intracranial aneurysms (within three days of rupture) who were treated using the Pipeline Embolization Device (PED) with adjunctive coil embolization...
April 2, 2024: World Neurosurgery
https://read.qxmd.com/read/38572014/has-the-role-of-veno-arterial-extracorporeal-membrane-oxygenation-in-patients-with-cardiogenic-shock-following-acute-myocardial-infarction-been-fully-determined-a-case-report
#15
Kha Minh Nguyen, Hai Phuong Nguyen Tran, Vi Tuong Dang, Sy Van Hoang
BACKGROUND: The persistent challenge of high mortality rates in acute myocardial infarction-induced cardiogenic shock endures notwithstanding advancements in the diagnosis and treatment of this disease over the past two decades. While recent studies present conflicting evidence on the efficacy of veno-arterial extracorporeal membrane oxygenation (VA ECMO), observational research supports the benefits of early VA ECMO initiation. However, the current lack of robust support from randomized clinical trials for VA ECMO use in this context highlights the ongoing uncertainty surrounding its effectiveness...
April 2024: European Heart Journal. Case Reports
https://read.qxmd.com/read/38567581/clinical-study-of-tirofiban-compared-to-low-molecular-weight-heparin-in-the-antithrombotic-treatment-of-progressive-pontine-infarction
#16
RANDOMIZED CONTROLLED TRIAL
Q Zhou, L-E Xu, L-L Lin, X-R Huang, W-Z Chi, J Lin, P Lin
OBJECTIVE: To investigate the efficacy and safety of tirofiban and low molecular weight heparin (LMWH) in the treatment of patients undergoing acute progressive pontine infarction. PATIENTS AND METHODS: Patients with acute progressive pontine infarction who were hospitalized in the Neurology Department from June 2021 to June 2023 were included in the study and randomly divided into two groups, namely the experimental group (tirofiban group) and the control group (LMWH group)...
March 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38567122/elective-hand-surgery-and-antithrombotic-use-in-veterans
#17
JOURNAL ARTICLE
Loretta Coady-Fariborzian, Peter Vonu, Christy Anstead
BACKGROUND: Patients undergoing plastic surgery have traditionally been instructed to avoid anticoagulants and antiplatelets during the perioperative period to avoid bleeding that could lead to painful hematomas, skin necrosis, unplanned procedures, and blood transfusions. Many veterans are currently prescribed anticoagulants for prevention of life- and limb-threatening embolic and thrombotic events. In early 2015, the plastic surgery service began to instruct patients undergoing elective hand surgery to stay on their prescription anticoagulant perioperatively...
November 2023: Federal Practitioner
https://read.qxmd.com/read/38563380/quantitative-benefit-risk-evaluation-of-rivaroxaban-in-patients-after-peripheral-arterial-revascularization-the-voyager-pad-trial
#18
JOURNAL ARTICLE
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd Haskell, Elliot S Barnathan, Marc P Bonaca
BACKGROUND: The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) trial compared rivaroxaban (2.5 mg twice a day) plus aspirin with aspirin alone in patients with symptomatic peripheral artery disease requiring endovascular or surgical limb revascularization, with 50% receiving clopidogrel background therapy...
April 2, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38557474/management-of-coagulopathy-among-patients-with-cirrhosis-undergoing-upper-endoscopy-and-paracentesis-persistent-gaps-and-areas-of-consensus-in-a-multispecialty-delphi
#19
JOURNAL ARTICLE
Elliot B Tapper, Matthew A Warner, Rajesh P Shah, Juliet Emamaullee, Nancy M Dunbar, Michelle Sholzberg, Jacqueline N Poston, Robin J Soto, Ammar Sarwar, Anjana Pillai, Karina Reyner, Shivang Mehta, Marwan Ghabril, Timothy R Morgan, Stephen Caldwell
Background and Aims Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio (INR) and low platelet count, but these do not correlate well with peri-procedure bleeding risk. We sought to develop consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the peri-procedure management of coagulopathy in cirrhosis. Approach and Results We identified candidate process measures for peri-procedure coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy...
April 1, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://read.qxmd.com/read/38555552/low-dose-prasugrel-versus-standard-dose-ticagrelor-in-east-asian-patients-with-acute-coronary-syndrome
#20
JOURNAL ARTICLE
Yee-Jen Wu, Chien-Chih Wu, Hsin-Yi Huang, Chi-Yun Wu, Ching-Chang Huang, Chi-Chuan Wang
Low-dose prasugrel demonstrated a similar effectiveness profile to clopidogrel in East Asian ACS patients, but its comparison with another new-generation potent P2Y12 inhibitor, ticagrelor, remains unclear. To compare the effectiveness and safety of low-dose prasugrel against those of standard-dose ticagrelor in East Asian patients with ACS. This retrospective cohort study used Taiwan's National Health and Welfare Database. This study included ACS patients who underwent percutaneous coronary intervention and, at discharge between January 1, 2018 and December 31, 2020, were prescribed with low-dose prasugrel plus aspirin or standard-dose ticagrelor plus aspirin...
March 31, 2024: Journal of Thrombosis and Thrombolysis
keyword
keyword
38548
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.